Copyright © 2015 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
Editor-in-Chief: Natalia Ortúzar
Impact Factor: 3.046
ISI Journal Citation Reports © Ranking: 2013: 18/58 (Chemistry Medicinal); 75/256 (Pharmacology & Pharmacy)
Online ISSN: 1860-7187
May 28, 2013
Development of new Antibiotics by GSK Gets $200 Million Boost from US Government
To support the development of new compounds in the fight against antibiotic resistance and bioterrorism, the US Department of Health and Human Services (HHS) has awarded GlaxoSmithKline up to $200 million in a first-of-its kind public–private agreement.
HHS will supply $40 million for the first 18 months of the project, and will provide up to $200 million provided the agreement between the US government and GSK is renewed over five years.
The government–private sector collaboration will permit funding to encompass GSK's antibacterial portfolio instead of being earmarked for a specific drug candidate, and will involve the study of drugs for the potential treatment of both conventional pathogens and those that pose a threat for their use in bioterrorism.
Many pharmaceutical companies have recently stopped antibacterial R&D efforts, citing scientific challenges and lower returns on investment. This naturally impedes the ability to treat bacterial infections and leads to vulnerability to biothreat pathogens. Such a public–private partnership should therefore be important in sustaining efforts in this area of medicinal chemistry.
Full details can be found in the recent GSK press release. Some recent relevant ChemMedChem articles include: